137 related articles for article (PubMed ID: 1771408)
1. Comparative studies on various assays for the laboratory evaluation of r-hirudin.
Walenga JM; Hoppensteadt D; Koza M; Pifarre R; Fareed J
Semin Thromb Hemost; 1991 Apr; 17(2):103-12. PubMed ID: 1771408
[TBL] [Abstract][Full Text] [Related]
2. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
3. In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood.
Kaiser B; Fareed J; Walenga JM; Hoppensteadt D; Markwardt F
Thromb Res; 1991 Dec; 64(5):589-96. PubMed ID: 1808763
[TBL] [Abstract][Full Text] [Related]
4. Methods for the monitoring of direct thrombin inhibitors.
Hafner G; Roser M; Nauck M
Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
[TBL] [Abstract][Full Text] [Related]
5. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
Choi TS; Khan AI; Greilich PE; Kroll MH
Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
[TBL] [Abstract][Full Text] [Related]
6. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
Pötzsch B; Madlener K; Seelig C; Riess CF; Greinacher A; Müller-Berghaus G
Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass.
Jormalainen M; Vento AE; Lukkarinen H; Kääpä P; Kytö V; Lauronen J; Paavonen T; Suojaranta-Ylinen R; Petäjä J
J Cardiothorac Vasc Anesth; 2007 Apr; 21(2):224-31. PubMed ID: 17418736
[TBL] [Abstract][Full Text] [Related]
9. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Meddahi S; Samama MM
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
[TBL] [Abstract][Full Text] [Related]
10. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
11. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of two enzyme-linked immunosorbent assay (ELISA) methods for recombinant hirudin.
Iyer L; Adam M; Amiral J; Fareed J; Bermes E
Semin Thromb Hemost; 1995; 21(2):184-92. PubMed ID: 7660141
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Boström SL; Hansson GF; Sarich TC; Wolzt M
Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
[TBL] [Abstract][Full Text] [Related]
14. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions.
Hoppensteadt DA; Walenga JM; Fareed J
Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369
[TBL] [Abstract][Full Text] [Related]
15. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
16. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
[TBL] [Abstract][Full Text] [Related]
17. A functional clotting assay to monitor the hirudin dosage.
Zakir RM; Hoffman W; Bhatt BA; Spillert CR
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):119-23. PubMed ID: 17287627
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
19. Monitoring the new antithrombotic drugs.
Walenga JM; Hoppensteadt DA
Semin Thromb Hemost; 2004 Dec; 30(6):683-95. PubMed ID: 15630675
[TBL] [Abstract][Full Text] [Related]
20. Clinical monitoring of hirudin and direct thrombin inhibitors.
Nowak G
Semin Thromb Hemost; 2001 Oct; 27(5):537-41. PubMed ID: 11668425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
